Livzon Pharmaceutical Group Inc. Livzon Pharmaceutical Group Inc.

Livzon Pharmaceutical Group Inc.

000513

Kedudukan dalam Saham #4689
Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and... Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and established in 1985, is a biopharmaceutical enterprise operating across the entire spectrum of pharmaceutical activities, from research and development to manufacturing and commercialization. The company's operations encompass a diverse range of finished drug products, active pharmaceutical ingredients (APIs), and chemical intermediates, primarily serving the Chinese market while also engaging in international exports. Its pharmaceutical portfolio includes treatments such as Ilaprazole enteric coated tablets for duodenal ulcers and reflux esophagitis, Laprazole sodium injection for managing peptic ulcer bleeding, Leuprorelin Acetate Microspheres for injection, and Urofollitropin injection for anovulation and fertility support. Livzon also produces Perospirone Hydrochloride for schizophrenia, Anti-viral Granules targeting upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, spontaneous sweating, and vertigo, and provides supportive care for lung and stomach cancer patients. Beyond therapeutic drugs, Livzon Pharmaceutical Group develops and distributes a variety of diagnostic reagents. These include kits for detecting IgM/IgG antibodies to coronavirus, nucleic acid tests for human immunodeficiency virus type 1, antinuclear antibody test kits, interferon-gamma release assay kits, and rapid tests for mycoplasma pneumoniae IgM antibodies. The company's extensive offerings further extend to biochemical drugs, microbiological preparations, biologics, traditional Chinese medicine formulations, pharmaceutical raw materials, and antibiotics.
Harga Saham
$3.90
Modal Pasaran
$3.17B
Perubahan (1 hari)
-3.49%
Perubahan (1 tahun)
-25.88%
Negara
CN
Perdagangan Livzon Pharmaceutical Group Inc. (000513)

Kategori

Healthcare
Margin Operasi untuk Livzon Pharmaceutical Group Inc. (000513)
Margin Operasi pada October 2026 TTM: 20.23%
Menurut laporan kewangan dan harga saham terkini Livzon Pharmaceutical Group Inc., margin operasi semasa (TTM) ialah 20.23%. Pada akhir 2024, margin operasi syarikat ialah 24.08%.
Sejarah Margin Operasi untuk Livzon Pharmaceutical Group Inc. dari 2001 hingga 2026
Margin Operasi pada akhir setiap tahun
Tahun Margin Operasi Ubah
2026 (TTM) 20.23% -8.17%
2025 22.03% -8.51%
2024 24.08% 23.93%
2023 19.43% 4.41%
2022 18.61% -0.96%
2021 18.79% -20.95%
2020 23.77% 28.97%
2019 18.43% 28.16%
2018 14.38% -78.32%
2017 66.32% 475.69%
2016 11.52% 10.13%
2015 10.46% -0.76%
2014 10.54% -17.59%
2013 12.79% 4.84%
2012 12.20% -10.23%
2011 13.59% -28.25%
2010 18.94% -15.71%
2009 22.47% 36.02%
2008 16.52% -2.02%
2007 16.86% 123.61%
2006 7.54% -6.91%
2005 8.10% 2.40%
2004 7.91% -9.81%
2003 8.77% 22.66%
2002 7.15% -7.50%
2001 7.73% 0.00%
Margin Operasi untuk syarikat serupa atau pesaing
Syarikat Margin Operasi Perbezaan Margin Operasi Negara
19.41% -99.04%
DE
19.68% -99.03%
DE
10.52% -99.48%
JP
17.08% -99.16%
CH
22.93% -98.87%
IN
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.